{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:08:41Z","timestamp":1788350921305,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the risk of myasthenia gravis (MG) associated with immune checkpoint inhibitors (ICI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse event (AE) reports related to MG, myasthenic syndrome, and MG crisis for durvalumab, atezolizumab, pembrolizumab, nivolumab, avelumab, and ipilimumab in the US FDA Adverse Event Reporting System (FAERS) from Q1 2004 to Q3 2022 were collected. The proportional reporting odds ratio (PRR) method was used to evaluate the correlation between the six drugs and the three AEs. Statistical significance was defined as having reports \u22653, PRR\u2009\u2265\u20092, and chi\u2010square (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>)\u2009\u2265\u20094.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 36, 78, 276, 380, 5, and 53 AE reports were collected for durvalumab, atezolizumab, pembrolizumab, nivolumab, avelumab, and ipilimumab, respectively. For myasthenic syndrome, the PRR values reflecting the correlation with the drugs were 27.83 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u2009102.66), 26.20 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u2009235.67), 44.17 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20091313.98), 32.09 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20091229.54), 21.31 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u2009151.15), and 0 for durvalumab, atezolizumab, pembrolizumab, nivolumab, avelumab, and ipilimumab, respectively. For MG, the PRR values reflecting the correlation with the drugs were 24.21 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u2009682.04), 18.34 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u2009900.27), 39.32 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20097945.15), 26.93 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20096636.45), 14.73 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u2009566.47), and 15.69 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200954.77) for durvalumab, atezolizumab, pembrolizumab, nivolumab, avelumab, and ipilimumab, respectively. For MG crisis, there were no data for durvalumab, atezolizumab, avelumab, and ipilimumab; the PRR values reflecting the correlation with the drugs were 16.54 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u2009225.23) and 9.20 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u2009119.14) for pembrolizumab and nivolumab, respectively. All six drugs were statistically correlated with their corresponding AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ICI may lead to ICIs\u2010associated MG during therapy. Analysis of FAERS data identified signals for AEs of MG with ICI regimens. Practitioners should consider the factors that may increase the likelihood of MG. The findings support a continued surveillance and risk factor identification.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6559","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T10:08:17Z","timestamp":1695118097000},"page":"19491-19499","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the <scp>US FDA<\/scp> Adverse Event Reporting System"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-8765","authenticated-orcid":false,"given":"Qingli","family":"Kong","sequence":"first","affiliation":[{"name":"Phase I Clinical Trial Laboratory Affiliated Hospital of Jining Medical University  Jining Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Affiliated Hospital of Jining Medical University  Jining Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Ren","sequence":"additional","affiliation":[{"name":"Medical Big Data Center Affiliated Hospital of Jining Medical University  Jining Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Affiliated Hospital of Jining Medical University  Jining Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Affiliated Hospital of Jining Medical University  Jining Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01317-7"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0557"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0221"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0078"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0714"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-484X.2017.04.029"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-020-00208-1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000re-search.21402.1"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.6039\/j.issn.1001-0408.2019.10.01"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0075-1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0043"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz411"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.038"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004359"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26689"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2020.102.25"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.229"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a41211"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e31815d4398"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30638"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932020-00006"},{"key":"e_1_2_9_31_1","unstructured":"Food and Drug Administration.FDA adverse event reporting system (FAERS).2021. Accessed August 16 2021.https:\/\/www.fda.gov\/drugs\/surveillance\/questions\u2010andanswers\u2010fdas\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1017391"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T06:40:23Z","timestamp":1718692823000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":31,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/cam4.6559"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6559","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"2023-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}